[Psoriasis and beta-blockade].
Psoriasiform skin eruptions during treatment with beta-adrenergic blocking drugs have recently attracted increasing attention and led the Bundesgesundheitsamt [German Office of Public Health] to publish general information on this issue. Today's knowledge on the clinical picture, pharmacology, and the pathogenesis is discussed, with reference to the latest experimental data. The blockade of keratinocyte beta-adrenergic receptors may play a key role in the aetiopathology of this unwanted side-effect.
Steinkraus
V
V
Hautklinik Universitäts-Krankenhaus Hamburg-Eppendorf.
Mensing
H
H
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D002455:Cell Division / Q000187:drug effects; D000242:Cyclic AMP / Q000378:metabolism; D003875:Drug Eruptions / Q000209:etiology*; D006801:Humans; D011565:Psoriasis / Q000139:chemically induced*; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D015398:Signal Transduction / Q000187:drug effects; D012867:Skin / Q000294:innervation
D000319:Adrenergic beta-Antagonists; D011943:Receptors, Adrenergic, beta; D000242:Cyclic AMP
Psoriasis und Beta-Blockade.